Krsnaa Diagnostics Limited has informed the Exchange about Transcript
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krsnaa Diagnostics filed the transcript of its Q4 & FY25 earnings call held on May 13, 2025. FY25 revenue grew 16% YoY to INR 7,172 million, with EBITDA up 34% to INR 1,958 million (27% margin, +370 bps) and net profit rising 37% to INR 776 million. Q4 revenue stood at INR 1,861 million (12% YoY) with 29% EBITDA margin. The board recommended a dividend of INR 2.75 per share. Management fell short of its 20-25% growth aspiration, citing delays in Maharashtra CT/MRI site handovers, early termination of the BMC project, and a conscious decision to cut exposure in receivables-stretched regions. The retail business (RPL brand) contributed 3.5% of Q4 revenue, with a 4x network expansion in its first year and a 5-8% revenue target for FY26.
Strong margin expansion (+370 bps) and 37% net profit growth are positives, but the 16% revenue growth missed the company's 20-25% aspiration, which may temper near-term sentiment. High receivables of INR 140-150 crores stuck in Himachal Pradesh and Karnataka (128 days vs 90 in other states) remain a key watchpoint, though management targets a recovery to 90-100 days by end of FY26.